{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:08:50Z","timestamp":1790222930598,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI123024"],"award-info":[{"award-number":["R01 AI123024"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["U01020776"],"award-info":[{"award-number":["U01020776"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment monitoring of drug-resistant tuberculosis (DR-TB) in resource-limited settings is challenging. We developed a multi-analyte assay for eleven anti-TB drugs in small hair samples as an objective metric of drug exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Small hair samples were collected from participants at various timepoints during directly observed RR-TB treatment at an inpatient tertiary referral facility in South Africa (DR-TB cohort). We assessed qualitative determination (i.e., detection above limit of detection) of bedaquiline, linezolid, clofazimine, pretomanid, levofloxacin, moxifloxacin, pyrazinamide, isoniazid, ethambutol, ethionamide, and prothionamide in an LC-MS\/MS index panel assay against a reference standard of inpatient treatment records. Because treatment regimens prior to hospitalization were not available, we also analyzed specificity (for all drugs except isoniazid) using an external cohort of HIV-positive patients treated for latent TB infection with daily isoniazid (HIV\/LTBI cohort) in Uganda.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 57 DR-TB patients (58% with pre-XDR\/XDR-TB; 70% HIV-positive) contributing analyzable hair samples, the sensitivity of the investigational assay was 94% or higher for all drugs except ethionamide (58.5, 95% confidence interval [CI], 40.7\u201399.9). Assay specificity was low across all tested analytes within the DR-TB cohort; conversely, assay specificity was 100% for all drugs in the HIV\/LTBI cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Hair drug concentrations reflect long-term exposure, and multiple successive regimens commonly employed in DR-TB treatment may result in apparent false-positive qualitative and falsely elevated quantitative hair drug levels when prior treatment histories within the hair growth window are not known.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-020-05738-5","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T01:02:58Z","timestamp":1611277378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Diagnostic accuracy of a liquid chromatography-tandem mass spectrometry assay in small hair samples for rifampin-resistant tuberculosis drug concentrations in a routine care setting"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-7036","authenticated-orcid":false,"given":"John","family":"Metcalfe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bacchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Esmail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Reckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie R.","family":"Muyindike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keertan","family":"Dheda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Gerona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"issue":"1","key":"5738_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/QAI.0000000000000221","volume":"67","author":"MR O'Donnell","year":"2014","unstructured":"O'Donnell MR, Wolf A, Werner L, Horsburgh CR, Padayatchi N. Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study. J Acquir Immune Defic Syndr. 2014;67(1):22\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"5738_CR2","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1086\/518665","volume":"196","author":"CD Wells","year":"2007","unstructured":"Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis. 2007;196(Suppl 1):S86\u2013107.","journal-title":"J Infect Dis"},{"issue":"2","key":"5738_CR3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1086\/380795","volume":"38","author":"P Gurumurthy","year":"2004","unstructured":"Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al. Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin Infect Dis. 2004;38(2):280\u20133.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"5738_CR4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1128\/AAC.50.2.407-413.2006","volume":"50","author":"SM Graham","year":"2006","unstructured":"Graham SM, Bell DJ, Nyirongo S, Hartkoorn R, Ward SA, Molyneux EM. Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection. Antimicrob Agents Chemother. 2006;50(2):407\u201313.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"5738_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1164\/rccm.200907-0989OC","volume":"181","author":"NR Gandhi","year":"2010","unstructured":"Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010;181(1):80\u20136.","journal-title":"Am J Respir Crit Care Med"},{"key":"5738_CR6","first-page":"1","volume":"856","author":"T Baciu","year":"2015","unstructured":"Baciu T, Borrull F, Aguilar C, Calull M. Recent trends in analytical methods and separation techniques for drugs of abuse in hair. Anal Chim Acta. 2015;856:1\u201326.","journal-title":"Anal Chim Acta"},{"key":"5738_CR7","unstructured":"Guidance for industry bioanalytical method validation. 2013. Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM368107.pdf."},{"issue":"2","key":"5738_CR8","first-page":"00046-2019","volume":"5","author":"JBP Metcalfe","year":"2019","unstructured":"Metcalfe JBP, Gerona R, Esmail A, Dheda K, Gandhi M. Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB. Eur Respir J Open. 2019;5(2):00046-2019.","journal-title":"Eur Respir J Open"},{"key":"5738_CR9","doi-asserted-by":"publisher","first-page":"121729","DOI":"10.1016\/j.jchromb.2019.121729","volume":"1125","author":"R Gerona","year":"2019","unstructured":"Gerona R, Wen A, Aguilar D, Shum J, Bacchetti P, Gandhi M, Metcalfe J. Simultaneous analysis of 11 medications for drug resistant TB in small hair samples to quantify adherence and exposure using a validate LC-MS\/MS panel. J Chromatogr B. 2019;1125:121729.","journal-title":"J Chromatogr B"},{"issue":"3","key":"5738_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/QAI.0000000000000154","volume":"66","author":"MD Hickey","year":"2014","unstructured":"Hickey MD, Salmen CR, Tessler RA, et al. Antiretroviral concentrations in small hair samples as a feasible marker of adherence in rural Kenya. J Acquir Immune Defic Syndr. 2014;66(3):311\u20135.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"5738_CR11","doi-asserted-by":"publisher","first-page":"121729","DOI":"10.1016\/j.jchromb.2019.121729","volume":"1125","author":"R Gerona","year":"2019","unstructured":"Gerona R, Wen A, Aguilar D, et al. Simultaneous analysis of 11 medications for drug resistant TB in small hair samples to quantify adherence and exposure using a validated LC-MS\/MS panel. J Chromatogr B Anal Technol Biomed Life Sci. 2019;1125:121729.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"5738_CR12","volume-title":"Stata statistical software: release 14","author":"StataCorp","year":"2015","unstructured":"StataCorp. Stata statistical software: release 14. College Station: StataCorp LP; 2015."},{"key":"5738_CR13","first-page":"18","volume":"41","author":"VS M R","year":"2011","unstructured":"M R VS. Segmental analysis of hair in an alleged drug facilitated sexual assault\u2014the pros and cons of segmental analysis and why results are rarely black and white. TIAFT Bull. 2011;41:18\u20139.","journal-title":"TIAFT Bull"},{"issue":"9","key":"5738_CR14","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1093\/jat\/bky038","volume":"42","author":"KN Gunther","year":"2018","unstructured":"Gunther KN, Johansen SS, Wicktor P, Banner J, Linnet K. Segmental analysis of chlorprothixene and desmethylchlorprothixene in postmortem hair. J Anal Toxicol. 2018;42(9):642\u20139.","journal-title":"J Anal Toxicol"},{"key":"5738_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jat\/20.1.1","volume":"20","author":"GL Henderson","year":"1996","unstructured":"Henderson GL, Harley MR, Zhou C, et al. Incorporation of isotopically labelled cocaine and metabolites into human hair: 1. Dose-response relationships. J Anal Toxicol. 1996;20:1\u201312.","journal-title":"J Anal Toxicol"},{"issue":"3","key":"5738_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/ACI.0b013e3283609831","volume":"13","author":"D Curran-Everett","year":"2013","unstructured":"Curran-Everett D, Milgrom H. Post-hoc data analysis: benefits and limitations. Curr Opin Allergy Clin Immunol. 2013;13(3):233\u20134.","journal-title":"Curr Opin Allergy Clin Immunol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05738-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-020-05738-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05738-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T01:03:23Z","timestamp":1611277403000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05738-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5738"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05738-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.14805\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.14805\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.14805\/v3","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,22]]},"assertion":[{"value":"13 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Permission to conduct the study was obtained from the University of Cape Town Human Research Ethics Committee (187\/2016), the Mbarara University of Science and Technology Research Ethics Committee (11\/10\u201316), and the University of California, San Francisco (UCSF) Human Research Protection Program (14\u201314609). All patients gave their written informed consent to participate in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors: No reported conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}